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Abstract
Microfluidics has become an important tool in diagnosing many diseases, including neurological and genetic
disorders. Alzheimer’s disease (AD) is a neurodegenerative disease that irreversibly and progressively destroys
memory, language ability, and thinking skills. Commonly, detection of AD is expensive and complex. Fluorescence
in situ hybridization (FISH)-based microfluidic chip platform is capable of diagnosing AD at an early stage and they
are effective tools for the diagnosis with low cost, high speed, and high sensitivity. In this review, we tried to
provide basic information on the diagnosis of AD via FISH-based microfluidics. Different sample preparations using
a microfluidic chip for diagnosis of AD are highlighted. Moreover, rapid innovations in nanotechnology for
diagnosis are explained. This review will provide information on dynamic quantification methods for the diagnosis
and treatment of AD. The knowledge provided in this review will help develop new integration diagnostic
techniques based on FISH and microfluidics.
Keywords: Fluorescence in situ hybridization (FISH), Microfluidic chip, Alzheimer’s disease (AD), Nanoparticles, Mole-
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Introduction
Fluorescence in situ hybridization (FISH) was developed
during the 1980s, for the detection of specific nucleic
acid sequences and cytogenetical analysis [1,2]. Further,
FISH has replaced conventional methods such as radioi-
sotope probe labeling [3]. Traditional FISH techniques
can safely and quantitatively detect many targets, but it
is a time-consuming process [4]. Recently, FISH-based
microfluidic technique was introduced and was shown
to have low cost and high speed. It also offers a number
of advantages such as lower amounts of sample and
reagents required, less energy, less time required, dispo-
sability, compact size, computerization, and trouble-free
analysis [5]. Microfluidics is useful for detecting differ-
ent kinds of samples, such as microorganisms [6], biolo-
gical materials (DNA, RNA) [7,8], enzymes [9],
antibodies [10,11], mammalian cells [12], and biomole-
cular interactions, and it can also be applied to environ-
mental monitoring, medical diagnostics, the food and
agricultural industries [6,13-15], and detection of genetic
disorders [5]. Such as the well known genetic diseases
are cardiovascular problems, diabetes, cancer, arthritis
and Alzheimer’sd i s e a s e s( A D )[ 1 6 ] .I n h e r i t a n c eo fA D
is complex [17,18] and involves language breakdown,
mental confusion, and memory loss [19]. AD was first
described by German psychiatrist Alois Alzheimer in
1906 [20]. It is a common and complex disease that has
various environmental and genetic aspects [21,22]. One
recent report found that 1 in 85 people worldwide will
have AD by 2050 [23].
Amyloid precursor protein (APP), presenilin 1 (PS-1),
and presenilin 2 (PS-2) and sporadic forms genes such
as apolipoprotein E (APOE) increase the risk for AD
later in life [24]. Therefore, early genetic-based diagnosis
is very important for managing AD. FISH-based micro-
fluidic analyses are highly suitable for the detection of
single nucleotide polymorphisms (SNP) [5]. Hence, bio-
markers and molecular probes are important to detect-
ing AD at an early stage [25]
Alternatively, peptide nucleic acid (PNA) probes can
be used for diagnosis instead of DNA probes or as com-
plementary probes to DNA. They exactly mimic DNA
probes and therefore one of the most powerful tools for
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can bind to complementary strand of DNA and RNA
sequences with high affinity and high specificity [26-28].
PNA-based FISH analyses are used for quantitative telo-
mere analysis using fluorescent-labeled PNA probes
[26]. Labeling analysis reveals human telomeric repeat
sequences and also can accurately estimate telomere
lengths [29]. PNA can also form a triplex with the target
double-stranded DNA [30]. Apart from this, duplex
invasion, double duplex invasion, and triplex invasion
binding are also possible [26]. Perhaps the detection of
DNA hybridization by electrochemical method was high
compassion, cheaper with advantage of microfabrication
technology [31] and using PNA probes for hybridization
is equally possible in this technology [32]. Moreover,
this PNA shows high affinity with DNA sequences, anti-
sense and antigen agents, biosensors, and molecular
probes [30].
This review attempted to summarize the requirements
for integrating FISH techniques with microfluidic tech-
nology for AD diagnosis. Since, AD detection is possible
at an early stage, which is an easy and cheaper detection
method. A detailed discussion concerning the detection
of AD is carried out.
FISH-Based Detection of Chromosomal
Abnormalities
Though the numbers of automated scanning systems are
commercially available, the visual based detection meth-
ods are most important for confirmation of results
[33,34]. FISH is a great system for identifying chromoso-
mal abnormalities. It can be applied to genetic mapping
and diagnosis of novel oncogenes, solid tumors, and var-
ious cytogenetic disorders. It also has achieved universal
acceptance as a clinical laboratory tool [35,36]. Most
importantly, microchip-based FISH techniques can
reduce labor time and cost [37]. The human chromo-
some has been analyzed biochemically and structurally
for cytogenetic investigations and diagnostics. FISH
technique can also be used to analyze chromosomal
details and localize a specific gene, and it is important
to develop the fluorescence microscopy [38].
Initially, AD was diagnosed by enzyme-linked immu-
noassays (ELISA), which is further extended to develop
nanoparticle-based bio barcode amplification analysis.
Bio barcode assay (BCA) is more than 1 million times
more sensitive compared to ELISA, and it uses amyloid
b derived diffusible ligands (ADDLs) as a marker. BCA
assay can also be used to diagnose AD with about 85%
accuracy, due to the high amount of ADDLs present in
the cerebrospinal fluid (CSF). However, the drawback of
obtaining the CSF sample from the spinal cords [39]. To
overcome this difficulty, researchers are trying to design
a test that uses blood and urine samples instead.
Recently, Ivan and colleagues reported that human
brain diseases such as AD, which are present in the
human brain and are associated with chromosomal disor-
ders [40-42]. In this research, chromosome 21 aneuploidy
in lymphocytes and fibroblasts cells of AD patients was
observed using FISH techniques [43-45]. In this study,
three kinds of DNA probes were used, including chromo-
some enumeration probes [46-48] micro detection
probes [49], and five color probes [40,33]. These probes
were used along with multicolor FISH techniques. Using
this technique, evaluated more than 480,000 neural cells
[40,50,51]. FISH analyses on five different chromosomes
a n d7 0 0 0n u c l e if r o ms e v e nb r a i nt i s s u es a m p l e sw e r e
carried out at the same time. The signals were captured
using a CCD camera by the quantitative FISH method
(cohu, 4910 series, cohu inc., San Deigo, CA) [40]. Sev-
eral proteins were identified as risk factors of AD, includ-
ing PS-I, APOE ε4, and amyloid b peptide. According to
Takako et al., the PS-I gene is found on chromosome
14q24.3. This single 14q24.3 locus can be detected by
FISH [52-54]. Amyloid b peptide is a risk factor for AD
and can be found in the urine of AD patients. When ana-
lyzed by Western blotting, 0.003 to 1.11 ng in 1 ml of
amyloid b peptide was obtained from a urine sample
[55]. (Table 1) Summarized the other biomarkers of AD
and their sample sources [56-65].
Other research has proved that FISH is an effective
detection technology for AD. Generally, premature cen-
tromere separation (PCD) is associated with numerous
human diseases [66]. PCD was analyzed using peripheral
blood lymphocytes samples of AD patients on chromo-
some 18. The comparative analysis was carried using
elderly samples (as control). FISH has proven that the
frequency of PCD is very high on chromosome 18 and
that this disease is associated with aneuploidy [67].
Table 1 List of biomarkers for Alzheimer disease and
their sample source
Factor Sample
Source
Biomarkers Ref
Histopathological
factors
Urine, Blood Amyloid beta
peptide
[55,56]
CSF Tau protein [57]
CSF Phosphorylated
tau
[58]
Genetic factor Blood,saliva APOE [59,60]
CSF, blood,
saliva
APP [61,62,60]
Blood PS-1 [63]
Blood PS-2 [63]
Synaptic pathological
factor
CSF ADDL [39]
Others CSF Somatostatin [64]
Blood Metal ions [65]
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causing AD, hence the blood lymphocytes in metaphase
stage have used for the cytogenetic analysis. Since indi-
viduals with AD contain a high amount of PCD at meta-
phase stage, disease detection in the micronucleus (MN)
of blood lymphocytes can be carried out using FISH.
For this reason the chromosome pancentromeric DNA
probes has been used [38,68]. FISH technique based
results and records have been established to develop
this research forth.
FISH is a sensitive technique for detecting cytogeneti-
cal disorders, but it also has some drawbacks. FISH ana-
lysis requires an efficient and experienced staff as well
as a large amount of expensive probes for the experi-
ment (Approximately $90 per slide). Chip-based analysis
requires 0.5 to 1 μl of probes, whereas conventional
FISH method requires 10 μl of probes. Microfluidic
chip-based FISH techniques reduce the cost by 10 to
20-fold [37,38,69,70] as some possible probes impede
the high cost effect.
As discussed before, PNA probes used in molecular
diagnostic and FISH-based detection [71] can be used to
diagnose neurodegenerative dementia, chromosomal dis-
orders such as Parkinson’s, frontotemporal dementia
(associated with chromosome 17), AD [72], and genomic
mutation or labeling of chromosomes [26]. PNA probes
are used for in situ hybridization to recognize human
chromosomes 1, 2, 7, 9, 11, 17, and 18 in metaphase
and interphase stage nuclei [73,74]. Multicolor PNA
probes are used for the samples such as lymphocytes,
aminocytes, and fibroblasts [54,75]. Based on the above
literature review, AD at an early stage can be detected
on chromosome 18 [67], chromosome 17 [72], and lym-
phocytes [68] by the FISH method. PNA oligomers can
be integrated with a micro total analysis system such as
microarray and automatic construction of PNA records
array [76,77]. Furthermore, DNA/DNA hybridization,
PNA/DNA hybridization, and antigen-antibody interac-
tion for proteins like APP is possible using a microflui-
dic chip [78].
Connection of Microfluidic Chip for Detection of
Alzheimer’s Disease
Highly qualified and efficient technicians spend several
hours performing conventional FISH protocol using
centromeric probes; it takes a minimum of 2-3 hours to
complete the process. However, anyone can manage
microfluidic chip-based FISH techniques, as only a few
minutes are required to complete this procedure. A
FISH-based microfluidic chip device can analyze thou-
sands of genes or thousands of patient samples at a sin-
gle time, and a technician only needs to spend a few
minutes [69]. Many types of analyzing materials are
used to study the nervous system [75]. Microfluidic
chips are one of the most useful devices for detecting
neurodegenerative diseases such as AD. For AD, early
identification is important as this type of neurodegen-
erative disease has dangerous effects in later life [25].
This can be combined with a micro electroporation chip
to detect other genetic disorders such as Huntington’s
disease, autosomal dominant Parkinson’sd i s e a s e ,a n d
charcot-marie-tooth disease [79-81]
Moreover, microfluidic chip is one of the most effec-
tive tools for disease detection; especially for genetic
based diagnoses and other biomedical applications
[82-88]. This microfluidic technique has evolved from
Micro Electro Mechanical Systems (MEMS). The
MEMS eliminated other critical biophysical, chemical
and biological analysis [89]. The main aim of this micro-
fluidic system is miniaturization. The major constituent
of the microfluidic chip is fabricating materials and con-
trolling the fluid flow [90]. The microfluidic chip
accommodates the test fluids and chemicals within the
channel to carry out the experiments, where the channel
size ranges from 10-100 μm or more in width. Basic
principles of microfluidics flow through the channel
could be characterized by the Reynolds Number, This is
described as Re = rvL/μ, where L is the most relevant
length scale, μ is the fluid viscosity, r is the fluid density
and v is the average velocity of the flow [91]. There are
two common processes for fluid motion: laminar flow
and electrokinetic flow. One of the basic laws of the
laminar flow is pressure and diffusion to distribution of
the molecules transported within the channel. The elec-
trokinetic flow needs electrohydrodynamic force
between the inlet and outlet port [92]. The microfluidic
device control the movement of fluids via force or elec-
trical energy and integrated optical system finds the
solutions of the particular experiment. Different kinds of
materials are used to make microfluidic chips and it is
useful for different kinds of biochemical analyses, parti-
cularly polydimethylsiloxane (PDMS) chips [85,87],
paper based chips, and thermoplastic chips, which are
very cheap. It also helpful in making inexpensive dispo-
sable chip and to avoid the cross contamination of bio-
logical samples [93-95]. Recently, advanced techniques
incorporated with microfluidic chips were developed for
optical, electrical, and mechanical sensing. This can be
achieved by connecting or attaching a CCD and CMOS
sensor to the microfluidic chip. FISH based chip method
shows high sensitivity even with a low amount of sam-
ple [96].
Microarray and BCA are major detection tools for bio-
logical analysis. Microarrays are a one of the micro total
analysis system (μTAS) and it is a direct method for the
detection of single nucleotide polymorphisms (SNPs).
However, microarrays require an expensive device for
analysis and require a long incubation period [97]. The
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tion (PCR). If the sample concentration is very low, the
immobilized sample should be fixed on a glass slide
using a microarray spotting machine [98]. It needs a
special scanner to analyze the microarray chip. Com-
pared to microarrays, microfluidic chips used for SNP
detection require less time and are more sensitive even
with a small amount of sample [97]. Ultra high-through-
put microfluidic chips are more reliable for disease diag-
n o s i sa si tf o c u s e so nS N Pa n a l y s i sf o rA Dd e t e c t i o n
and can lead to the development of drugs for SNP.
Microfluidic chips have the ability to perform hundreds
of reactions and can synthesis up to 10,000 compounds
per chip [99].
BCA is a sensitive analytical method for detection of
AD and other diseases. It can also be used as a disease-
monitoring device and for the analysis of disease mar-
kers [39,100]. Moreover, BCA system used to detect
amyloid b protein, which is a hallmark of AD [39].
Microfluidic chips have replaced many laboratory tools,
including BCA, due to its portability, automation, and
simplicity. Hence, BCA continues to be the next stage
of development for surface-immobilized BCA
[39,100,101], but its working format resembles a micro-
fluidic chip. Integrated microfluidic barcode chips
increase the sensitivity of the detection [97,102]. BCA
proved the several considerable and new analytical
potentialities, though it is not even in its most favorable
form. To analyze the target DNA sequence it needs
three different kinds of oligonucleotides like magnetic
particle capture sequence, universal sequence and bar-
code capture strand, it is synthetically demanding and
expensive. Hybridization of barcode DNA with support
strands on Au-NP surface is extremely difficult to attain
100% loading consistently. Skilled person are required
for operating this system and should follow several
safety procedures when using human samples [103].
Also they have limitation to use the different colors of
fluorescent labels in BCA [95,104] and it needs reader
like verigene ID to find out the data [47]. But the micro-
fluidic chip has designed with an encapsulated BCA,
surface immobilized BCA. This single device is simple,
inexpensive, and can be used in many applications such
as chemical reactors, sensors, and more [100,102].
FISH is carried out as an automatic method on a
microfluidic chip, as illustrated in Figure 1. Sieben et al.,
used a microfluidic chip which is useful for distinguish-
ing the chromosomal defects from PBMC cells. The cell
suspension were mixed with PBS and introduced in the
microchannel by capillary force. This chip should be
heated to improve the cell attachment on the channel
surface. These cells were treated with proteinase K. The
Proteinase K is allowed to digest the cells, and also it is
helpful to enter the respective DNA probes with
fluorescence into the cells [37]. By using this technique,
the detection of chromosomal defects and genetic analy-
sis are possible within 1 hour. This is an important
technique to reach the next level in this field. This
method is fast, inexpensive and automated genetic
screening is applied to distin g u i s ht h es p e c i f i cc h r o m o -
somes defects (aneuploidy) and other related disorders
[105]. AD is a major aneuploidy-related disorder. Per-
ipheral blood lymphocytes [40,67] and primary fibroblast
cell samples are used for the detection of AD [44].
Since, the microfluidic chip could be accomplished
using the raw blood samples, which gives genetic infor-
mation for many kinds of genetic disorders [99]. This
microfluidic chip also can be applied to analysis of urine
samples [106], the AD diagnosis could be possibly done
by detecting the amyloid b peptide, which is obtained
from the urine [55]. Recent types of microfluidic chips
Figure 1 Analysis of blood sample using FISH based on
microfluidic chip. Blood samples introduced into the microfluidic
chip by capillary force and cells were attached on the channel
surface by heating the microfluidic chip. Then Proteinase K
introduced into the chip to digest the cells, followed by increasing
the temperature of microfluidic chip for few sec to denature the
DNA, then fluorescence tagged DNA probes introduced into the
chip. Complementary DNA probes hybridized with the target
sequence and emit fluorescence.
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time by 10-fold [99].
Sample Preparation Method for Microfluidic Chip-
Based Diagnosis of Alzheimer’s Disease
Sample preparation plays a major role in microfluidic
chip-based analysis. Easy sample preparation helps
reduce the difficulties of analysis in a short period of
time. Chip-based analysis is an authentic technique like
PCR, capillary electrophoresis, FISH [103], and other
technologies that use nano wires [107] and nano pores
[108]. In conventional methods, nucleic acid sample pre-
paration has high labor cost and requires many steps to
isolate nucleic acids from raw materials like blood,
spinal fluid, saliva, and tissue. This method takes a long
time to prepare the sample for biological analysis
[109-111]. However, microfluidic chip-based systems
a v o i dt h ed i f f i c u l t i e so fs a m p l ep r e p a r a t i o n ,a si ti sa
simple method with low cost and reagent consumption
[112]. Microfluidic chip-based systems also do not
require any spinning method. Chip-based sample pre-
paration miniaturizes the entire laboratory tool in a sin-
gle device with micro fabrication method and it replaces
the costly equipment used for biological laboratory and
clinical field [112]. This lab on chip sample preparation
leads to the development of home-based self-analysis.
The sample preparation includes two major steps: 1)
cell lysis and 2) DNA, RNA extraction, as shown in Fig-
ure 2 Cell lysis is classified into four major types: 1)
mechanical lysis 2) thermal lysis 3) chemical lysis, and
4) electrical lysis [112]. Lysis techniques aim to rupture
the cell wall and release cell cytoplasm. For mechanical
lysis, the cell membranes disturbed with mechanical
force such as microknives [112,113], poly methylsiloxane
(PDMS) membrane [114], ultra sonication [115,116],
and laser beam irradiation have been used [117] to
release the cytoplasm. APP can be obtained by rupturing
the single membrane of CSF cells. APP has about 590-
680 amino acids present in the cytoplasmic tail [61].
The mismetabolism of APP increases the risk of AD.
Hence, measuring the amount of APP in CSF would
help detect AD [118]. Although, APP is traditionally
measured by Western blotting [119], however the blot-
ting technique does not produce accurate measure-
ments. Therefore, it is not a truly quantitative method
for APP measurement in CSF [118].
Thermal lysis is a pertinent technique for DNA and
RNA isolation and involves heating the sample at 100°C
for 40 sec in boiling water. The technique is enough to
obtain nucleic acids without any damage [120,121].
Microheating is an advanced technique that can be inte-
grated within a microfluidic chip to isolate cell samples
from blood and other sources [122]. As we discussed in
Section 1, obtaining sample from the CSF is very
difficult and painful, although very accurate. To avoid
this problem, researchers have developed, blood sample-
based methods for detection of AD using FISH techni-
ques and microfluidic chips. Blood lymphocytes used for
AD detection along with FISH have shown positive
results [67]. Since AD is associated with chromosome
21 of human blood, the soluble form of APP can be iso-
lated from human platelets. This isolated APP can be
confirmed by immunological methods and Western
blotting techniques [62].
Chemical lysis is the other important method for
microfluidic-based sample preparation [112]. This can
be carried out using buffers and lytic agents such as
ammonium chloride [119], SDS, lysozyme, chaotropic
salts, b-mercaptoethanol, and Triton-X4 that maintain
protein structure and function [123-126]. Amyloid b
peptide is normally released from cells that contain
small 42 residue proteins fragments. Any person with a
decreased amount of amyloid b peptides in CSF would
be prone to develop AD [56], which has been confirmed
by many studies [127]. The electrical lysis method
requires electrical force to lyse the cell membrane. High
intensity pulsed electric fields [PEFs] are suitable techni-
ques for microfluidic applications, and it increases the
frequency in the μTAS analysis system [128,129]. The
advantage of an electrical lysis system with an integrated
microfluidic chip is reduced electrical power
Figure 2 Sample preparation using microfluidic system: Cell
lysis and Nucleic acid extraction method. Cell lysis is rupture of
cell membrane and release of cell components by using cell lysis
methods such as a) Mechanical lysis b) Thermal lysis c) Chemical
lysis d) Electrical lysis. Nucleic acid extraction is the isolation of DNA
and RNA from the cells using microfluidic chip by a)Silica-based
surface affinity b) Electrostatic interaction c) Nanoporous membrane
filtration d) Functionalized microparticles
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to lyse mammalian cells with competence of 74% at low
power [130]. From the above discussion, it is clear that
any lysis method can be integrated into a microfluidic
chip.
From the existing literature, it can be clearly under-
stood that detection at the molecular level surely has an
impact on AD diagnosis. Microfluidic chip-based DNA
separation can give positive results. As we reported,
microfluidic-based DNA separation can be classified
into four types: 1) silica-based surface affinity, 2) electro-
static interaction, 3) nanoporous membrane filtration,
and 4) functionalized microparticles [112].
Increased surface affinity and high ionic solutions are
helpful in binding DNA to glass fiber and silica, due to
low electrostatic repulsion and wash out the DNA with
low ionic strength buffer. This is the common proce-
dure for DNA extraction. Chaotropic salt solutions have
confirmed the results of DNA adsorption and deso-
rption with nanogram quantities of silica resins in
microfabricated devices, showing ~70% binding capacity
in white blood cells [131]. On the other hand, hybrid
architectures of microfabricated devices of silica beads
and sol-gel matrix produce ~90% DNA extraction
within 15 min [132,133]. However, the drawbacks of
hybrid architecture are bonding and shrinkage, which
affect the DNA extraction quantity and purity of the
sample. Developing tetramethylorthosilicate [TMOS]-
based sol-gel matrices with micro pore tools could avoid
this problem, thus offering promising potential by
extracting DNA from human CSF and viral DNA
[134,135]. APOE (chromosome 19) from human blood
leukocytes cells can also be used for AD detection.
Usually, the conventional method for isolation of the
APOE gene takes a long time, approximately 6-8 hours,
and also requires gene amplification [59]. On the other
hand, microfluidic-based DNA preparation and identifi-
cation is faster and requires a smaller amount of sample.
Further, AD patients contain a high amount of tau-pro-
tein in their CSF [57]. Conventional methods measure
tau protein by ELISA [136], which can measure 10 pg/
ml of tau-protein in CSF. Using microfluidic chip-based
techniques, tau protein can be measured in combination
with high throughput analysis methods such as surface
plamon resonance (SPR) [137].
APOE is a glycoprotein containing 299 amino acids and
with a molecular weight of 34.2 kDa [138]. Usually, APOE
genes are used as biomarkers for individuals suspected of
having AD [52]. APOE is classified into three major forms,
ApoE2, ApoE3, and ApoE4, the allelic forms of which are
e2, e3, and e4, respectively [139]. Generally, an individual
containing the e2 allelic form is not at risk for AD. How-
ever, an individual containing the e3 or e4 allelic form is at
higher risk to AD at early stage [52].
Integrated silicon-based microfluidic chips are useful
for cell lysis and DNA extraction from whole blood
[140], and they are very easy to handle [141]. Another
method for DNA extraction is based on electrostatic
interactions. Chitosan-coated microfluidic chips are
often used for DNA extraction from whole blood and
cell lysis at pH levels near 5, with a rate of isolation of
68% for human genomic DNA [142]. Functionalized
microparticles and magnetic beads are used for sample
preparation with the aid of an integrated microfluidic
chip [112]. Genetic diseases can be detected by obtain-
ing DNA from cells in the saliva [143]. The risk for AD
of APP and amyloid b proteins isolated from saliva was
analyzed by ELISA [60]. Functionalized magnetic beads
were used for saliva sample preparation with the help of
lysis buffer. This method could isolate and purify DNA
within 10 min [143]. After sample preparation, the
microfluidic chip can be used to identify the results.
Nanomaterials Coupled With Fluorescent Probes
for Diagnosis of Alzheimer’S Disease
A pertinent technique is being developed for the optical
detection of molecular disease [144]. Organic and inor-
ganic-based nanomaterials exhibit immense potential
and have excellent physicochemical visual magnetic
properties, which can be easily manipulated [145-147].
Gold nanoparticles, quantum dots, and magnetic nano-
particles are used for diagnosis. Among these, gold
nanoparticles play a major role in sensing applications
and can be used as a multiprobe tool for visual inspec-
tion, fluorescence, Raman scattering, atomic and mag-
netic force, and electrical conductivity. In situ
hybridization with nanoparticles can provide sensitive
results. FISH coupled with nanoparticles has provided
remarkable detection in both prokaryotic [148] eukaryo-
tic cells [149]. A microfabricated device coupled with
n a n o p a r t i c l e si s1 0 0 , 0 0 0t i m e sm o r es p e c i f i ca n d1 0
times more sensitive for DNA detection than modern
genomic detection systems. The targeted disease
sequence DNA presented in the sample on the chip
could be bound with gold nanoparticle. Further, addi-
tional use of silver solution in the microfluidic chip can
produce accurate detection with a minute amount of
DNA [144]. In nanoparticle-based DNA detection, a
multiple number of DNA probes could bind and detect
millions of DNA sequences simultaneously. Further, it
leads to the sensor based detection for the different
types of biological materials [144,150].
In molecular diagnosis, the nanoparticles are used as a
nanoscale material due to their low toxicity, easy pairing
with biomolecules, and their adaptability in various
detection methods for analyses. Nanoparticle-based
microfluidic analysis for biomolecules can produce the
data by Fluorescence Raman Scattering or Optical
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dic chips allow the device to concentrate and amplify
signals from gold particles [151]. Biotin-labeled PNA
probes immobilized on the gold surface could bind with
the DNA target sequence with high affinity [152].
Nanoparticles are used in many microscale diagnostic
devices such as microarrays and BCA. A microfluidic
chip with nanoparticles is used for recognizing specific
DNA sequences and can be confirmed by fluorescence
detection. Gold nanoparticles are incorporated into the
channel wall of the microfluidic chip. The DNA probes
are then linked to the monolayer through thiol groups
at one end and the fluorescence dye at the other end.
Hybridization and detection of target genes can be car-
ried out via in situ hybridization on the microfluidic
channel. Therefore, this is a promising method for clini-
cal diagnosis [153].
Silver nanoparticles are also useful for DNA detection
applications even at a low sample concentration. An
integrated PDMS microfluidic chip with high sensitivity
when coupled with nanoparticles allows detection in
confocal and non-confocal modes [98]. Nanoparticle-
based detection of DNA hybridization and protein bind-
ing can be carried out by label-based and label-free
methods. Label-based detection uses fluorescent nano-
particle labels. On the other hand, label-free detection
uses sensor, SPR, surface enhance Raman scattering, and
cantilever-based biosensor to detect microfluidic data in
the laboratory. However, quantitative and sensitive
detection is required for taking these methods to the
next level of disease treatment [154]. Localized SPR of
nanoparticles can be used to detect tau-protein in CSF
even at picogram quantities [137]. Further, CMOS sen-
sors used for DNA hybridization detection have been
reported in micro fabricated devices [155]. These self-
analytical tools are cheap, sensitive, and user-friendly.
They can also be incorporated into cell phones, digital
cameras, and scanners to enumerate the results and
documentation [156,157].
Future Perspectives
There are many methods and devices used to detect
AD, including microarray technology, BCA, microfluidic
platform, and antigen antibody-based detection. All of
these techniques can be used for biological and clinical
analysis. Prevention or early detection is the best solu-
tion for avoiding cytogenetic and other dangerous disor-
ders. Patients might be unaware until harmful
symptoms are felt. Usually, AD detection is a costly pro-
cedure. Hence we tried to develop a cost-effective,
microchip-based AD and genetic-based diagnostic tech-
niques for early diagnosis. Self-analyses are available for
the detection of flu-like illnesses and colds. A physician
can treat patients based on the data obtained from self-
analysis. In the future, detecting AD could be made
easier using FISH integrated with a microfluidic chip.
This detection system would be possible at any stage of
the disease. Genetic analysis is the most effective
method for biological analysis and disease diagnosis
using tissue, body fluids, and microbial analysis. DNA-
based detection is a promising method for detecting the
suppressed stage of genes. This detection method can
be improved as a self-analyzing tool by using a single
chip. Above all, this will be a cheaper method and the
detection will be molecular level in every clinical visit.
This kind of diagnosis will help reduce the number of
individuals with AD in the future. This integrated
microfluidic chip will be used widely not only for AD
treatment but also for all neurobiological diseases.
Moreover, the sample collection will not be a challen-
ging task, and detection can be possibly carried out by
using blood samples and urine.
Summary
This review discussed the stages and causes of AD. Con-
ventional detection methods of AD have been using bio-
molecules obtained from CSF. The detection of AD
using FISH techniques and microfluidic chip technology
has been carried out in an appropriate manner. Detailed
DNA isolation starting from cell lysis was also discussed.
The role of nanomaterials in the detection of genetic
disease using DNA was reviewed as well. This review
envisioned FISH techniques incorporated with micro-
fluidic devices as an innovative diagnostic tool. This
method would be helpful for genetic level analysis and
early stage analysis of diseases. This single chip will be
useful for multiple analyses of DNA hybridization, pro-
tein analysis, and other quantitative-based analysis.
As revealed by FISH, microfluidic chip and nanoparti-
cle-based analyses are very effective for diagnosing AD.
Our aim is to join all of these effective techniques
together. An integrated system would achieve biotherapy
of genetic diseases. This work has increased our under-
standing of AD using microfluidic chips. These fusion
techniques will be a common and sensitive tool for all
the biological techniques.
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